EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Genetically engineered, attenuated whole-cell vaccine approaches for malaria

Ashley M Vaughan, Ruobing Wang, Stefan H I Kappe

Human Vaccines · 2010-01 · 6 (1) · 107-113

DOI: 10.4161/hv.6.1.9654 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Vaccines, online erschienen am 27.10.2014. Verfasst von Ashley M Vaughan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Seattle Biomedical Research Institute, Seattle, WA, USA. Die Arbeit wurde bisher 95-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria remains one of the most significant infectious diseases affecting human populations in developing countries. The quest for an efficacious malaria vaccine has been ongoing for nearly a century with limited success. The identification of malaria parasite antigens focused efforts on the development of subunit vaccines but has so far yielded only one partially efficacious vaccine candidate, RTS/S. The lack of high vaccine efficacy observed to date with subunit vaccine candidates raises doubts that the development of a single antigen or even a multi-antigen malaria subunit vaccine is possible. Fortunately, it has been demonstrated in animal studies and experimental clinical studies that immunizations with live-attenuated sporozoite stages of the malaria parasite confer long lasting, sterile protection against infection, providing a benchmark for vaccine development. These early successful vaccinations with live-attenuated malaria parasites did not however, promote a developmental path forward for such a vaccine approach. The discovery of genetically engineered parasite strains that are fully attenuated during the early asymptomatic liver infection and confer complete sterile protection in animal malaria models support the development of a live attenuated sporozoite vaccine for Plasmodium falciparum and its accelerated safety and efficacy testing in malaria challenge models and in malaria endemic areas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HumansMalaria VaccinesMalaria, FalciparumPlasmodium falciparumSporozoitesVaccines, Attenuated

Substanzen

Malaria VaccinesVaccines, Attenuated

Autor:innen und Institutionen

  • Seattle Biomedical Research Institute, Seattle, WA, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Vaughan, A. M., Wang, R., & Kappe, S. H. (2010). Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Human Vaccines, 6(1), 107-113. https://doi.org/10.4161/hv.6.1.9654

Vancouver

Vaughan AM, Wang R, Kappe SH. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Human Vaccines. 2010;6(1):107-113. doi:10.4161/hv.6.1.9654

BibTeX
@article{Vaughan2010,
  author = {Vaughan, Ashley M and Wang, Ruobing and Kappe, Stefan H I},
  title = {Genetically engineered, attenuated whole-cell vaccine approaches for malaria},
  journal = {Human Vaccines},
  year = {2010},
  volume = {6},
  number = {1},
  pages = {107--113},
  doi = {10.4161/hv.6.1.9654}
}
Kostenlos starten →